156 related articles for article (PubMed ID: 25819575)
1. Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater.
Schiergens TS; Reu S; Neumann J; Renz BW; Niess H; Boeck S; Heinemann V; Bruns CJ; Jauch KW; Kleespies A
Surgery; 2015 Jul; 158(1):151-61. PubMed ID: 25819575
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study.
Moekotte AL; Malleo G; van Roessel S; Bonds M; Halimi A; Zarantonello L; Napoli N; Dreyer SB; Wellner UF; Bolm L; Mavroeidis VK; Robinson S; Khalil K; Ferraro D; Mortimer MC; Harris S; Al-Sarireh B; Fusai GK; Roberts KJ; Fontana M; White SA; Soonawalla Z; Jamieson NB; Boggi U; Alseidi A; Shablak A; Wilmink JW; Primrose JN; Salvia R; Bassi C; Besselink MG; Abu Hilal M
Br J Surg; 2020 Aug; 107(9):1171-1182. PubMed ID: 32259295
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy.
Jiang ZQ; Varadhachary G; Wang X; Kopetz S; Lee JE; Wang H; Shroff R; Katz M; Wolff RA; Fleming J; Overman MJ
Ann Oncol; 2013 Sep; 24(9):2349-53. PubMed ID: 23704197
[TBL] [Abstract][Full Text] [Related]
4. [Combined application of immunohistochemical markers to identify pathologic subtypes of ampullary carcinoma and its clinical significance].
Liu FF; Shen DH; Wang HL; Ma YT; Yuan F; Liu J; Chen L; Song QJ; Zhang YY
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):92-97. PubMed ID: 30695858
[No Abstract] [Full Text] [Related]
5. Differential Expression of β-Catenin, EGFR, CK7, CK20, MUC1, MUC2, and CDX2 in Intestinal and Pancreatobiliary-Type Ampullary Carcinomas.
Perysinakis I; Minaidou E; Leontara V; Mantas D; Sotiropoulos GC; Tsipras H; Zografos GN; Margaris I; Kouraklis G
Int J Surg Pathol; 2017 Feb; 25(1):31-40. PubMed ID: 27543509
[TBL] [Abstract][Full Text] [Related]
6. Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
Ecker BL; Vollmer CM; Behrman SW; Allegrini V; Aversa J; Ball CG; Barrows CE; Berger AC; Cagigas MN; Christein JD; Dixon E; Fisher WE; Freedman-Weiss M; Guzman-Pruneda F; Hollis RH; House MG; Kent TS; Kowalsky SJ; Malleo G; Salem RR; Salvia R; Schmidt CR; Seykora TF; Zheng R; Zureikat AH; Dickson PV
JAMA Surg; 2019 Aug; 154(8):706-714. PubMed ID: 31141112
[TBL] [Abstract][Full Text] [Related]
7. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Neoptolemos JP; Moore MJ; Cox TF; Valle JW; Palmer DH; McDonald AC; Carter R; Tebbutt NC; Dervenis C; Smith D; Glimelius B; Charnley RM; Lacaine F; Scarfe AG; Middleton MR; Anthoney A; Ghaneh P; Halloran CM; Lerch MM; Oláh A; Rawcliffe CL; Verbeke CS; Campbell F; Büchler MW;
JAMA; 2012 Jul; 308(2):147-56. PubMed ID: 22782416
[TBL] [Abstract][Full Text] [Related]
8. Clinico-pathological correlates and survival outcomes in 214 resected ampullary adenocarcinomas - are outcomes different in intestinal and pancreatobiliary subtypes with adjuvant gemcitabine?
Ramaswamy A; Bhandare M; Bal M; Shrirangwar S; Kataria P; Majumdar S; Swami R; Rohila J; Chaudhari V; Mandavkar S; Chavan N; Shrikhande SV; Ostwal V
HPB (Oxford); 2020 Mar; 22(3):376-382. PubMed ID: 31405778
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
Jin Z; Hartgers ML; Sanhueza CT; Shubert CR; Alberts SR; Truty MJ; Muppa P; Nagorney DM; Smyrk TC; Hassan M; Mahipal A
Eur J Surg Oncol; 2018 May; 44(5):677-683. PubMed ID: 29506768
[TBL] [Abstract][Full Text] [Related]
10. Lymph node involvement and not the histophatologic subtype is correlated with outcome after resection of adenocarcinoma of the ampulla of vater.
de Paiva Haddad LB; Patzina RA; Penteado S; Montagnini AL; da Cunha JE; Machado MC; Jukemura J
J Gastrointest Surg; 2010 Apr; 14(4):719-28. PubMed ID: 20107918
[TBL] [Abstract][Full Text] [Related]
11. Survival analysis of pancreatic and periampullary collision cancers.
Niu GM; Jin DY; Ji Y; Hou J; Wang DS; Lou WH
J Dig Dis; 2010 Aug; 11(4):231-6. PubMed ID: 20649736
[TBL] [Abstract][Full Text] [Related]
12. Differentiation and prognostic markers in ampullary cancer: Role of p53, MDM2, CDX2, mucins and cytokeratins.
Perysinakis I; Minaidou E; Mantas D; Sotiropoulos GC; Leontara V; Tsipras H; Zografos GN; Margaris I; Kouraklis G
Pathol Res Pract; 2016 Nov; 212(11):1039-1047. PubMed ID: 27688085
[TBL] [Abstract][Full Text] [Related]
13. Better outcome of XELOX chemotherapy in patients with advanced intestinal-type adenocarcinoma of the ampulla of Vater.
Kim HS; Shin SJ; Kim JH; Kim H; Choi HJ
Tohoku J Exp Med; 2013 Sep; 231(1):21-8. PubMed ID: 23994910
[TBL] [Abstract][Full Text] [Related]
14. Intestinal and pancreatobiliary differentiation in periampullary carcinoma: the role of immunohistochemistry.
Kumari N; Prabha K; Singh RK; Baitha DK; Krishnani N
Hum Pathol; 2013 Oct; 44(10):2213-9. PubMed ID: 23834763
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
Chu PG; Schwarz RE; Lau SK; Yen Y; Weiss LM
Am J Surg Pathol; 2005 Mar; 29(3):359-67. PubMed ID: 15725805
[TBL] [Abstract][Full Text] [Related]
16. Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.
Shoji H; Morizane C; Hiraoka N; Kondo S; Ueno H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
Jpn J Clin Oncol; 2014 Apr; 44(4):324-30. PubMed ID: 24482413
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical Classification of Ampullary Carcinomas: Critical Reappraisal Fails to Confirm Prognostic Relevance for Recently Proposed Panels, and Highlights MUC5AC as a Strong Prognosticator.
Xue Y; Reid MD; Balci S; Quigley B; Muraki T; Memis B; Xia J; Hacihasanoglu E; Bedolla G; Pehlivanoglu B; Kim GE; Tajiri T; Ohike N; Aneja R; Krasinskas AM; Adsay V
Am J Surg Pathol; 2017 Jul; 41(7):865-876. PubMed ID: 28505002
[TBL] [Abstract][Full Text] [Related]
18. Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma.
Overman MJ; Soifer HS; Schueneman AJ; Ensor J; Adsay V; Saka B; Neishaboori N; Wolff RA; Wang H; Schnabel CA; Varadhachary G
BMC Cancer; 2016 Aug; 16(1):668. PubMed ID: 27549176
[TBL] [Abstract][Full Text] [Related]
19. The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma.
Showalter TN; Zhan T; Anne PR; Chervoneva I; Mitchell EP; Yeo CJ; Rosato EL; Kennedy EP; Berger AC
J Gastrointest Surg; 2011 Aug; 15(8):1411-6. PubMed ID: 21523621
[TBL] [Abstract][Full Text] [Related]
20. The clinicopathologic and immunohistochemical characteristics of ampulla of Vater carcinoma: the intestinal type is associated with a better prognosis.
Roh YH; Kim YH; Lee HW; Kim SJ; Roh MS; Jeong JS; Jung GJ
Hepatogastroenterology; 2007 Sep; 54(78):1641-4. PubMed ID: 18019683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
